Page last updated: 2024-10-15
edifoligide
Description
edifoligide: a short piece of double-stranded DNA that mimics the consensus binding sequence for E2F (E2F decoy); used for the prevention of infrainguinal vein graft failure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Research Excerpts
Overview
Edifoligide is an oligonucleotide decoy that binds to and inhibits E2F transcription factors. It may prevent neointimal hyperplasia and vein graft failure.
| Excerpt | Reference |
|---|---|
| "Edifoligide (E2F Decoy) is a novel therapy that inhibits E2F function, thus attenuating neointimal hyperplasia." | ( Design and rationale of the PREVENT III clinical trial: edifoligide for the prevention of infrainguinal vein graft failure. Bandyk, DF; Clowes, AW; Conte, MS; Lorenz, TJ; Moneta, GL; Seely, BL, ) |
| "Edifoligide is an oligonucleotide decoy that binds to and inhibits E2F transcription factors and thus may prevent neointimal hyperplasia and vein graft failure." | ( Efficacy and safety of edifoligide, an E2F transcription factor decoy, for prevention of vein graft failure following coronary artery bypass graft surgery: PREVENT IV: a randomized controlled trial. Alexander, JH; Califf, RM; Ferguson, TB; Gennevois, D; Gibson, M; Goyal, A; Hafley, G; Harrington, RA; Kouchoukos, NT; Lorenz, TJ; Mack, MJ; Peterson, ED, 2005) |
Toxicity
| Excerpt | Reference |
|---|---|
| " Other end points included other angiographic variables, adverse events through 30 days, and major adverse cardiac events." | ( Efficacy and safety of edifoligide, an E2F transcription factor decoy, for prevention of vein graft failure following coronary artery bypass graft surgery: PREVENT IV: a randomized controlled trial. Alexander, JH; Califf, RM; Ferguson, TB; Gennevois, D; Gibson, M; Goyal, A; Hafley, G; Harrington, RA; Kouchoukos, NT; Lorenz, TJ; Mack, MJ; Peterson, ED, 2005) |
| "66), on any secondary angiographic end point, or on the incidence of major adverse cardiac events at 1 year (101 [6." | ( Efficacy and safety of edifoligide, an E2F transcription factor decoy, for prevention of vein graft failure following coronary artery bypass graft surgery: PREVENT IV: a randomized controlled trial. Alexander, JH; Califf, RM; Ferguson, TB; Gennevois, D; Gibson, M; Goyal, A; Hafley, G; Harrington, RA; Kouchoukos, NT; Lorenz, TJ; Mack, MJ; Peterson, ED, 2005) |
Dosage Studied
| Excerpt | Reference |
|---|---|
| " Further studies are indicated to determine optimal dosing in this population and to definitively address the question of relationship to graft patency." | ( Statins are independently associated with reduced mortality in patients undergoing infrainguinal bypass graft surgery for critical limb ischemia. Beckman, JA; Belkin, M; Conte, MS; Hevelone, N; Owens, CD; Schanzer, A, 2008) |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (18)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 15 (83.33) | 29.6817 |
| 2010's | 3 (16.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 7 (36.84%) | 5.53% |
| Reviews | 2 (10.53%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 10 (52.63%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||